Alpha-ketoglutarate (α-KG), a TCA cycle intermediate, rescues human periodontal ligament stem cells (HPDLSCs) from LPS-induced senescence by restoring mitochondrial membrane potential, suppressing mitochondrial ROS accumulation, and reactivating the LKB1-AMPK signaling axis. In vitro, α-KG reduced senescence-associated β-galactosidase activity and downregulated P16 and P53 expression while recovering osteogenic differentiation capacity. In a ligature-induced rat periodontitis model, oral α-KG administration reduced alveolar bone loss and restored periodontal AMPK signaling in vivo.
This finding sits at the productive intersection of metabolic reprogramming and stem cell biology — a field gaining momentum since α-KG was identified as an epigenetic regulator through TET enzyme and histone demethylase activity. What distinguishes this work is the mechanistic specificity: α-KG's rescue of LKB1 expression provides a plausible upstream explanation for AMPK reactivation, connecting metabolic substrate availability directly to an energy-sensing kinase cascade. AMPK's role in suppressing cellular senescence via mitophagy and mTOR inhibition is well-established, making this axis biologically coherent.
Practically, α-KG is already commercially available as a dietary supplement, lending potential translational relevance. However, critical limitations temper enthusiasm: the in vitro model uses LPS as a reductionist inflammagen, the rat model lacks human tissue complexity, and no pharmacokinetic data confirm sufficient α-KG delivery to periodontal tissues orally. This is solid mechanistic groundwork — confirmatory of α-KG's broader anti-senescence profile — but human clinical validation remains entirely absent.
